Autism Spectrum DisorderNCT05811507
Evaluation of Serum Adrenal Androgens Among Prepubertal and Pubertal Boys With Autism Spectrum Disorder
An observational study of Autism Spectrum Disorder, run by Sohag University at 1 site in Egypt.
Trial summary
Autism spectrum disorder (ASD) is a neurodevelopmental disorder of unclear etiology. There are theories depicting the importance of sex steroid hormones in autism, since the prevalence of the disorder is male-biased. What makes boys more vulnerable to achieve the diagnosis of autism remains unclear. Read more about this study
- Who is it for?
- Ages 6 to 18 years, men only
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate, The Childhood Autism Rating Scale (CARS) and DSM-5 Diagnostic Criteria for ASD
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- Apr 2023to Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 18 years
- Men only
- Child, Adult
Study population: Age: 6-18 years. Proved diagnosis by clinical manifestations of ASD in addition to DSM-V Criteria. Assessment of ASD severity by Childhood Autism Rating Scale (CARS)
Who may be able to join
- Age: 6-18 years
- Proved diagnosis by clinical manifestations of ASD in addition to DSM-V Criteria
- Assessment of ASD severity by Childhood Autism Rating Scale (CARS)
Who cannot join
- Those with history of metabolic and neurodegenerative disease
- Medication History: Those on long-term use of antibiotics, non-steroidal drugs, immune-stimulants or immune-suppressive drugs
- Those with structural brain abnormalities
- Those with audiological or visual problems
- Those with other psychiatric problems
- Those with history of systemic illness as allergic disease, immunodeficiency or autoimmune disease
Trial locations and contacts
1 site in 1 country.
Abdelrahim A sadek, professor contact
About this study
Autism spectrum disorder (ASD) is a neurodevelopmental disorder of unclear etiology. There are theories depicting the importance of sex steroid hormones in autism, since the prevalence of the disorder is male-biased. What makes boys more vulnerable to achieve the diagnosis of autism remains unclear. One of the theories strengthens the importance of fetal organizational effect of testosterone on brain development. Baron Cohen with coworkers showed that elevated fetal levels of several androgens including testosterone were high in male-fetuses who later in postnatal life achieved the diagnosis of autism and fetal testosterone levels were positively correlated with autistic traits in general population.
Females with conditions of abnormal prenatal exposure to testosterone and its sex steroid precursors, such as congenital adrenal hyperplasia and polycystic ovary syndrome, were found to have higher rate of autistic traits as well as their children were of higher risk of developing autism. However, the exact mechanism by which these hormones influence the manifestation of autistic traits remains undiscovered. Another model explaining higher prevalence of ASD in males is a female protective model which suggests that multiple genetic factors contribute to the development of ASD and that higher threshold of genetic liability is required in females compared to males. Zhang et al. demonstrated genetic evidence of sex differences in ASD confirming female protective model, employing investigation of de novo mutations, common variants of ASD candidate genes and their co-expression in male and female brain.
Read more
During infancy: The Gonadotropin releasing hormone (GnRH) pulse generator is reactivated by 6 to 10 days after birth. This period, termed the mini puberty of infancy, was first described in the 1970s. During mini puberty, luteinizing hormone (LH) levels approximate pubertal concentrations, reaching a peak between 16 and 20 days of life. Serum testosterone levels rise in response to rising concentrations of LH, paralleling an increase in Leydig cell number and testicular testosterone concentrations. Serum testosterone levels peak from 1 to 3 months (210 ± 130 ng/dL or 7.28 ± 4.51 nmol/L on day of life 30) and decline by roughly 50% per month reaching prepubertal levels by 7 to 12 months of age. Dihydrotestosterone (DHT) concentrations parallel the rise in testosterone, reaching pubertal values during the early postnatal period.
During puberty: Testosterone is produced primarily by the testes, though a small amount is also made in the adrenal gland. Gonadarche refers to the onset of sex steroid production from the gonads and occurs in response to pulsatile production of GnRH from the hypothalamus, which in turn stimulates production of LH and Follicle stimulating hormone (FSH) from the pituitary gland. LH stimulates the Leydig cells to produce testosterone, whereas FSH stimulates the Sertoli cells to proliferate and initiate spermatogenesis.
Active androgens are synthesized via two alternative pathways. The first of them is known as the classic "frontdoor" pathway with pregnenolone serving as androgen precursor, which underwent a conversion to DHEA and subsequently to androstenediol. These metabolic steps are catalyzed by CYP17A1 (in the C17,20-lyase step) and (mostly adrenal) AKR1C3 enzyme, respectively. Dehydroepiandrosterone (DHEA) and androstenediol are readily sulfated by SULT2A1 in adrenal cortex and their sulfates serve as the stock pool for the production of active androgens of the adrenal origin as the production of androgens in early childhood of boys is limited to extra-gonadal tissues, such as adrenal, skin, etc. These sulfated primary androgens may be subsequently deconjugated and metabolized by HSD3B1 and HSD3B2 isoforms to androstenedione and Total testosterone (TST) and then to 5α/β-reduced 17-oxo- and 17β-androgens, respectively. In addition, the androstenedione may be readily converted to testosterone by adrenal AKR1C3. From the aforementioned substances, TST, 5α-dihydrotestosterone, and 11-oxo-testosterone are known as the most potent bioactive androgens. Besides the "frontdoor" pathway the dihydrotestosterone may be also formed by so called "backdoor" pathway. This pathway is based on a direct conversion of 5α/β-reduced pregnane steroids (C21) to their 5α/β-reduced androgen (C19) metabolites which is catalyzed by the same enzyme converting pregnenolone to DHEA (CYP17A1 in the C17,20-lyase step). These 5α/β-reduced androgen (C19) metabolites include also the most active androgen 5α-dihydrotestosterone. The "backdoor" pathway is crucial for androgen synthesis in marsupials but may also be active in various human steroid-related disorders.
- Conditions
- Autism Spectrum Disorder
- Being tested
- serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate, The Childhood Autism Rating Scale (CARS), DSM-5 Diagnostic Criteria for ASD, Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):
- Medical subject headings
- Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfateDiagnostic test
Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
The Childhood Autism Rating Scale (CARS)Diagnostic test
It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
DSM-5 Diagnostic Criteria for ASDDiagnostic test
Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):Diagnostic test
IQ Score ranges for the Stanford-Binet:
Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+
| Study group | Role | What they receive |
|---|---|---|
| Cases group of patients: | It will include patients with autism spectrum disorder.. Receives: Diagnostic Test: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate; Diagnostic Test: The Childhood Autism Rating Scale (CARS); Diagnostic Test: DSM-5 Diagnostic Criteria for ASD; Diagnostic Test: Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales): | |
| control group of patients: | It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases. Receives: Diagnostic Test: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate; Diagnostic Test: The Childhood Autism Rating Scale (CARS); Diagnostic Test: DSM-5 Diagnostic Criteria for ASD; Diagnostic Test: Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales): |
What is being measured
The primary outcome is the main question the study is designed to answer.
serum total testosterone level.
serum total testosterone level will be measured in (nglml).
Measured: baseline
serum dehydroepiandrosterone sulfate (DHEAS) level
serum dehydroepiandrosterone sulfate (DHEAS) will be measured in (mcgldl)
Measured: baseline
serum androsterone level
serum androsterone level will be measured in (nglml)
Measured: baseline
serum androstenedione level
serum androstenedione level will be measured in (nglml)
Measured: baseline
Assessment of severity of autism
Assessment of severity of autism by Childhood Autism Rating Scale (CARS)
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2023
- Study startApr 2023 (estimated)
- Primary completionApr 2024 (estimated)
- Study completionApr 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Salma Samir Ismail, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05811507
- Sponsor's protocol ID
- Soh-Med-23-03-03MD
- Status last verified
- Apr 2023
- First submitted
- 15 Mar 2023
- Last updated
- 13 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Baron-Cohen S, Auyeung B, Norgaard-Pedersen B, Hougaard DM, Abdallah MW, Melgaard L, Cohen AS, Chakrabarti B, Ruta L, Lombardo MV. Elevated fetal steroidogenic activity in autism. Mol Psychiatry. 2015 Mar;20(3):369-76. doi: 10.1038/mp.2014.48. Epub 2014 Jun 3.
PubMed 24888361Cherskov A, Pohl A, Allison C, Zhang H, Payne RA, Baron-Cohen S. Polycystic ovary syndrome and autism: A test of the prenatal sex steroid theory. Transl Psychiatry. 2018 Aug 1;8(1):136. doi: 10.1038/s41398-018-0186-7.
PubMed 30065244Robinson EB, Lichtenstein P, Anckarsater H, Happe F, Ronald A. Examining and interpreting the female protective effect against autistic behavior. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5258-62. doi: 10.1073/pnas.1211070110. Epub 2013 Feb 19.
PubMed 23431162Zhang Y, Li N, Li C, Zhang Z, Teng H, Wang Y, Zhao T, Shi L, Zhang K, Xia K, Li J, Sun Z. Genetic evidence of gender difference in autism spectrum disorder supports the female-protective effect. Transl Psychiatry. 2020 Jan 15;10(1):4. doi: 10.1038/s41398-020-0699-8.
PubMed 32066658
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Serum Adrenal Androgens Among Prepubertal and Pubertal Boys With Autism Spectrum Disorder
- ClinicalTrials.gov ID
- NCT05811507
- Acronym / sponsor ID
- Soh-Med-23-03-03MD
- Conditions
- Autism Spectrum Disorder
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Apr 2023 (estimated)
- Primary completion
- Apr 2024 (estimated)
- Study completion
- Apr 2024 (estimated)
- First posted
- 13 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder of unclear etiology. There are theories depicting the importance of sex steroid hormones in autism, since the prevalence of the disorder is male-biased. What makes boys more vulnerable to achieve the diagnosis of autism remains unclear. One of the theories strengthens the importance of fetal organizational effect of testosterone on brain development. Baron Cohen with coworkers showed that elevated fetal levels of several androgens including testosterone were high in male-fetuses who later in postnatal life achieved the diagnosis of autism and fetal testosterone levels were positively correlated with autistic traits in general population.
Females with conditions of abnormal prenatal exposure to testosterone and its sex steroid precursors, such as congenital adrenal hyperplasia and polycystic ovary syndrome, were found to have higher rate of autistic traits as well as their children were of higher risk of developing autism. However, the exact mechanism by which these hormones influence the manifestation of autistic traits remains undiscovered. Another model explaining higher prevalence of ASD in males is a female protective model which suggests that multiple genetic factors contribute to the development of ASD and that higher threshold of genetic liability is required in females compared to males. Zhang et al. demonstrated genetic evidence of sex differences in ASD confirming female protective model, employing investigation of de novo mutations, common variants of ASD candidate genes and their co-expression in male and female brain.
During infancy: The Gonadotropin releasing hormone (GnRH) pulse generator is reactivated by 6 to 10 days after birth. This period, termed the mini puberty of infancy, was first described in the 1970s. During mini puberty, luteinizing hormone (LH) levels approximate pubertal concentrations, reaching a peak between 16 and 20 days of life. Serum testosterone levels rise in response to rising concentrations of LH, paralleling an increase in Leydig cell number and testicular testosterone concentrations. Serum testosterone levels peak from 1 to 3 months (210 ± 130 ng/dL or 7.28 ± 4.51 nmol/L on day of life 30) and decline by roughly 50% per month reaching prepubertal levels by 7 to 12 months of age. Dihydrotestosterone (DHT) concentrations parallel the rise in testosterone, reaching pubertal values during the early postnatal period.
During puberty: Testosterone is produced primarily by the testes, though a small amount is also made in the adrenal gland. Gonadarche refers to the onset of sex steroid production from the gonads and occurs in response to pulsatile production of GnRH from the hypothalamus, which in turn stimulates production of LH and Follicle stimulating hormone (FSH) from the pituitary gland. LH stimulates the Leydig cells to produce testosterone, whereas FSH stimulates the Sertoli cells to proliferate and initiate spermatogenesis.
Active androgens are synthesized via two alternative pathways. The first of them is known as the classic "frontdoor" pathway with pregnenolone serving as androgen precursor, which underwent a conversion to DHEA and subsequently to androstenediol. These metabolic steps are catalyzed by CYP17A1 (in the C17,20-lyase step) and (mostly adrenal) AKR1C3 enzyme, respectively. Dehydroepiandrosterone (DHEA) and androstenediol are readily sulfated by SULT2A1 in adrenal cortex and their sulfates serve as the stock pool for the production of active androgens of the adrenal origin as the production of androgens in early childhood of boys is limited to extra-gonadal tissues, such as adrenal, skin, etc. These sulfated primary androgens may be subsequently deconjugated and metabolized by HSD3B1 and HSD3B2 isoforms to androstenedione and Total testosterone (TST) and then to 5α/β-reduced 17-oxo- and 17β-androgens, respectively. In addition, the androstenedione may be readily converted to testosterone by adrenal AKR1C3. From the aforementioned substances, TST, 5α-dihydrotestosterone, and 11-oxo-testosterone are known as the most potent bioactive androgens. Besides the "frontdoor" pathway the dihydrotestosterone may be also formed by so called "backdoor" pathway. This pathway is based on a direct conversion of 5α/β-reduced pregnane steroids (C21) to their 5α/β-reduced androgen (C19) metabolites which is catalyzed by the same enzyme converting pregnenolone to DHEA (CYP17A1 in the C17,20-lyase step). These 5α/β-reduced androgen (C19) metabolites include also the most active androgen 5α-dihydrotestosterone. The "backdoor" pathway is crucial for androgen synthesis in marsupials but may also be active in various human steroid-related disorders.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases group of patients: | – | Diagnostic Test: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate, Diagnostic Test: The Childhood Autism Rating Scale (CARS), Diagnostic Test: DSM-5 Diagnostic Criteria for ASD, Diagnostic Test: Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):It will include patients with autism spectrum disorder.. |
| control group of patients: | – | Diagnostic Test: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate, Diagnostic Test: The Childhood Autism Rating Scale (CARS), Diagnostic Test: DSM-5 Diagnostic Criteria for ASD, Diagnostic Test: Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases. |
Who may qualify
- Ages
- 6 to 18 years
- Sex
- Male only
- Age groups
- Child, Adult
- Study population
- Age: 6-18 years. Proved diagnosis by clinical manifestations of ASD in addition to DSM-V Criteria. Assessment of ASD severity by Childhood Autism Rating Scale (CARS)
Key inclusion criteria (3 listed)
- Age: 6-18 years
- Proved diagnosis by clinical manifestations of ASD in addition to DSM-V Criteria
- Assessment of ASD severity by Childhood Autism Rating Scale (CARS)
Key exclusion criteria (6 listed)
- Those with history of metabolic and neurodegenerative disease
- Medication History: Those on long-term use of antibiotics, non-steroidal drugs, immune-stimulants or immune-suppressive drugs
- Those with structural brain abnormalities
- Those with audiological or visual problems
- Those with other psychiatric problems
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfateVenous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA | Diagnostic test | Cases group of patients:, control group of patients: |
| The Childhood Autism Rating Scale (CARS)It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism | Diagnostic test | Cases group of patients:, control group of patients: |
| DSM-5 Diagnostic Criteria for ASDPersistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay. | Diagnostic test | Cases group of patients:, control group of patients: |
| Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):IQ Score ranges for the Stanford-Binet: Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+ | Diagnostic test | Cases group of patients:, control group of patients: |
Primary outcome
serum total testosterone level.
Time frame: baseline
serum total testosterone level will be measured in (nglml).
serum dehydroepiandrosterone sulfate (DHEAS) level
Time frame: baseline
serum dehydroepiandrosterone sulfate (DHEAS) will be measured in (mcgldl)
serum androsterone level
Time frame: baseline
serum androsterone level will be measured in (nglml)
serum androstenedione level
Time frame: baseline
serum androstenedione level will be measured in (nglml)
Assessment of severity of autism
Time frame: baseline
Assessment of severity of autism by Childhood Autism Rating Scale (CARS)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2023.
- Background: PubMed 24888361Baron-Cohen S, Auyeung B, Norgaard-Pedersen B, Hougaard DM, Abdallah MW, Melgaard L, Cohen AS, Chakrabarti B, Ruta L, Lombardo MV. Elevated fetal steroidogenic activity in autism. Mol Psychiatry. 2015 Mar;20(3):369-76. doi: 10.1038/mp.2014.48. Epub 2014 Jun 3.
- Background: PubMed 30065244Cherskov A, Pohl A, Allison C, Zhang H, Payne RA, Baron-Cohen S. Polycystic ovary syndrome and autism: A test of the prenatal sex steroid theory. Transl Psychiatry. 2018 Aug 1;8(1):136. doi: 10.1038/s41398-018-0186-7.
- Background: PubMed 23431162Robinson EB, Lichtenstein P, Anckarsater H, Happe F, Ronald A. Examining and interpreting the female protective effect against autistic behavior. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5258-62. doi: 10.1073/pnas.1211070110. Epub 2013 Feb 19.
- Background: PubMed 32066658Zhang Y, Li N, Li C, Zhang Z, Teng H, Wang Y, Zhao T, Shi L, Zhang K, Xia K, Li J, Sun Z. Genetic evidence of gender difference in autism spectrum disorder supports the female-protective effect. Transl Psychiatry. 2020 Jan 15;10(1):4. doi: 10.1038/s41398-020-0699-8.
- Individual participant dataSharing planned: Yes
Related trials for Autism Spectrum Disorder
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Abdelrahim A sadek, professor contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autism Spectrum Disorder, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Salma S Samir, assistant lecturer (01016470453, salma.abdelrehem@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
serum total testosterone level. (time frame: baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05811507, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2023.